Form 4: Alnylam Pharmaceuticals Executive Sells Shares Under 10b5-1 Plan

Pushkal Garg, CMO & EVP of Development and Medical Affairs at Alnylam Pharmaceuticals, sold 1,743 shares of common stock on December 12, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Pushkal Garg, the Chief Medical Officer and Executive Vice President of Development and Medical Affairs at Alnylam Pharmaceuticals, sold a total of 1,743 shares of the company's common stock on December 12, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 11, 2024.
• The transactions occurred at various prices, ranging from $247.48 to $255.80 per share.
• The sales were conducted in multiple transactions with weighted average prices reported for each block of sales.
• Following these transactions, Mr. Garg directly owns 15,705 shares of Alnylam common stock.
• He also indirectly owns 431 shares through a managed account and 250 shares through a trust.

Sentiment

Score: 5

Explanation: The document reflects a routine stock sale by an executive under a pre-arranged plan. It is neither particularly positive nor negative, and is a normal part of corporate activity.

Risks

• Executive stock sales, even under pre-arranged plans, can sometimes be perceived negatively by the market, potentially impacting investor sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often part of compensation packages or personal financial planning. The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology and pharmaceutical sectors, such as Regeneron Pharmaceuticals and Vertex Pharmaceuticals.
• These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The volume of shares sold by Mr. Garg is relatively small compared to the overall market capitalization of Alnylam, and is not unusual for an executive exercising a pre-planned trading strategy.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or long-term prospects.
• The sale does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Alnylam Pharmaceuticals, Pushkal Garg, stock sale, Rule 10b5-1, executive, insider trading, share transaction